• Press
  • Offices
  • Contact
  • Legal notice
  • LinkedIn
  • EN
    • DE
  • UPC
  • Firm
    • Main Focus
    • History
    • Guiding Principle
    • Code of Conduct
    • Awards and Rankings
  • Our Practice
    • Legal Areas
    • Industries
  • Our Team
  • News & Events
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Publications
    • B&B Bulletin
  • Career
  • Menu Menu
FIND EXPERTS
  • UPC
  • Firm
  • News & Events
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Publications
    • B&B Bulletin
  • FIND EXPERTS
  • Contact
  • Our Practice
  • Career
  • Offices
  • EN
    • DE
  • Legal Areas
  • Industries
Dr. Ute Kilger, Patent Attorney at BOEHMERT & BOEHMERT

Challenges for the bio­pharma­ceutical sector posed by US policy – article by Dr. Ute Kilger in Euro­pean Bio­tech­nology

30. October 2025/in Publications Patents and Utility Models

Article by Dr. Ute Kilger on the pressure exerted by the US government on the bio­pharma­ceutical industry and the consequences.

In the fall 2025 issue of European Biotechnology, BOEHMERT & BOEHMERT partner and patent attorney Dr. Ute Kilger explains the impact of US policy on the pharmaceutical and biotech industries in her article “Challenges for the biopharmaceutical sector posed by US policy”.

Dr. Kilger states that both the US and Europe are facing considerable challenges. Measures taken by the US government, such as the Inflation Reduction Act (IRA), the Orange Book initiative, the planned Most Favored Nation pricing regulation, and the proposed Trump-Lutnick patent tax, could hinder innovation and make investment in small molecule drugs unattractive.

In doing so, US policy favors generic drug entry and puts innovative companies under pressure. European companies are also affected, especially those that are heavily dependent on the US market. The EU is pursuing similar trends but has toned down some proposals following criticism from industry. If Europe acts decisively, it could benefit from the US measures and overtake the US in terms of innovative strength, concludes Dr. Kilger.

The full article by Dr. Kilger in English can be found in the fall issue of European Technology starting on page 33 and is available online here.

 

https://www.boehmert.de/wp-content/uploads/2022/06/Kilger-Ute-Portrait-Web.jpg 667 1000 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2025-10-30 11:15:462025-10-30 12:05:46Challenges for the bio­pharma­ceutical sector posed by US policy – article by Dr. Ute Kilger in Euro­pean Bio­tech­nology

Three BOEHMERT & BOEHMERT partners to speak at the international IP Forum on November 1, 2025 in Taipei

28. October 2025/in Events

Dr. Ute Kilger, Dr. Markus Engelhard and Dr. Sebastian Engels to speak at the forum “Intellectual Property in Innovative Business Models – Make IP your Asset”.

On 1 November 2025, the international forum “Intellectual Property in Innovative Business Models – Make IP your Asset” will take place in Taipei (Taiwan). Organized by NTU College of Medicine, SPARK and Jesse Lin, Co-founder of Bio-Innovation Taiwan, the event is aimed at professionals from academia and industry who focus on innovative business models and the strategic use of intellectual property. The spotlight will be on start-ups as well as small and medium-sized biotech and life sciences companies.

The three BOEHMERT & BOEHMERT speakers – Dr. Ute Kilger (Patent Attorney and Partner, Berlin), Dr. Markus Engelhard (Patent Attorney and Partner, Munich), and Dr. Sebastian Engels (Attorney at Law and Partner, Berlin) – will explore key legal aspects throughout the lifecycle of intellectual property: from acquisition and protection to commercialization, management and monitoring, particularly in light of technological transformation driven by AI.

In addition, a panel discussion featuring the three IP experts from BOEHMERT & BOEHMERT will delve deeper into the topic of IP lifecycle. Further details on the program – available only in Chinese – can be found in the event flyer.

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Lucia Biehl /wp-content/uploads/2022/04/boehmert_logo.svg Lucia Biehl2025-10-28 13:33:112025-10-29 11:31:23Three BOEHMERT & BOEHMERT partners to speak at the international IP Forum on November 1, 2025 in Taipei

C. W. Appelt, Dr. Engelhard, and Prof. Dr. Goddar named IAM Global Leaders 2026

23. October 2025/in Awards & Rankings

Three BOEHMERT & BOEHMERT partners and patent attorneys are featured in the current list of “IAM Global Leaders 2026”.

Every year, IAM honors some of the world’s leading IP specialists by including them in its list of “IAM Global Leaders.” To be eligible, candidates must have previously received a gold-level award in IAM Patent 1000 and demonstrate outstanding expertise coupled with a high degree of innovation and inspiration.

Among these 17 specially highlighted “IAM Global Leaders” for 2026 are also the BOEHMERT & BOEHMERT partners and patent attorneys Christian W. Appelt, Dr. Markus Engelhard, and Prof. Dr. Heinz Goddar.

Regarding Christian W. Appelt’s work, IAM says: “Christian Appelt is highly experienced in handling opposition and appeal proceedings, and does an excellent job in oral proceedings. He is appreciated for his professional and genuine advice.”

The jury said of Dr. Markus Engelhard: “Markus Engelhard is very reliable, practical, efficient and showcases perfect communication with the various parties involved in the patent prosecution process. He brings particularly strong skills in the life sciences, and is an essentail pillar of support for his clients’ success.”

IAM justified the award to Prof. Dr. Goddar as follows: “Heinz Goddar brings abundant experience in drafting patent applications and managing extensive patent portfolios for globally renowned companies. His deep knowledge and close attention to detail ensure the long-term protection of his clients’ valuable inventions.”

IAM also conducted an in-depth interview with each of the award-winning patent attorneys about their expertise and experience. These interviews are available at the following links:

  • Interview with Christian W. Appelt
  • Interview with Dr. Markus Engelhard
  • Interview with Prof. Dr. Heinz Goddar
Christian W. Appelt, Patent Attorney at BOEHMERT & BOEHMERT
Christian W. Appelt, Patent Attorney at BOEHMERT & BOEHMERT
Dr. Markus Engelhard, Patentanwalt BOEHMERT & BOEHMERT
Dr. Markus Engelhard, Patentanwalt BOEHMERT & BOEHMERT
Prof. Dr. Heinz Goddar, Patent Attorney at BOEHMERT & BOEHMERT
Prof. Dr. Heinz Goddar, Patent Attorney at BOEHMERT & BOEHMERT
/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2025-10-23 16:10:382025-10-23 16:12:14C. W. Appelt, Dr. Engelhard, and Prof. Dr. Goddar named IAM Global Leaders 2026

First Substantive Decisions of the UPC Court of Appeal: Seoul Viosys and Philips v. Belkin

20. October 2025/in UPC-Update

The decisions provide initial legal certainty on issues of disclosure, interpretation, infringement, and directors’ liability.

1. Context and Significance

In October 2025, the Court of Appeal of the Unified Patent Court (UPC) issued its long-awaited first substantive decisions: (i) the decision in Seoul Viosys (UPC_CoA_764/2024 & 774/2024) concerning added subject-matter, and (ii) the decision in Philips v. Belkin (UPC_CoA_534/2024, 19/2025, 683/2024) addressing infringement, claim interpretation, and directors’ liability.

These judgments – coming just over two years after the launch of the UPC system – mark the beginning of a true harmonisation of substantive patent law within the framework of the UPCA.

2. The Seoul Viosys Decision (CoA 764/2024 & 774/2024)

In its first substantive decision, the Court of Appeal dealt with the question of whether the granted claims extended beyond the content of the application as originally filed. The defendant in the infringement proceedings had filed a counterclaim for revocation based on added subject-matter. While the court of first instance had upheld the patent, the Court of Appeal reversed that decision and revoked the patent.

The Court confirmed that the relevant test for added subject-matter under Article 65(2) UPCA and Article 138(1)(c) EPC corresponds to the so-called “gold standard” of the EPO: the skilled person must be able to derive the claimed subject-matter directly and unambiguously from the original disclosure, taking into account their common general knowledge. An implicit disclosure is sufficient only if it is the inevitable consequence of what is expressly disclosed.

Particular importance was given to the issue of divisional applications. The Court held that the disclosure must be found not only in the divisional application itself, but also in any earlier application in the chain of filings – including parent and grandparent applications. The deletion of features or the combination of elements from different embodiments may amount to an impermissible intermediate generalisation unless the remaining combination is itself clearly and unambiguously disclosed as a general teaching. Applying this test, the Court found that the patent contained added subject-matter and therefore revoked it.

Commentators have noted that the reasoning closely follows EPO case law, while at the same time representing an autonomous application of these principles under the UPCA. The decision thus establishes a strict disclosure standard as the benchmark for assessing patent validity before the UPC.

3. The Philips v. Belkin Decision (CoA 534/2024, 19/2025 & 683/2024)

In its second substantive decision, the Court of Appeal dealt with several appeals arising from an infringement case before the Munich Local Division. Philips had asserted European Patent EP 2 867 997 against several Belkin entities and their managing directors. The first instance had found infringement and issued injunction, recall, and destruction orders. The Court of Appeal used the case to clarify key issues of infringement law – in particular, claim interpretation, the notion of “offering,” and personal liability of managing directors.

4. Claim Interpretation

The Court confirmed a functional, expert-oriented approach to claim interpretation. The key question was whether a transmitter that only sends a signal of “acceptance” fulfils a claim feature referring to “acceptance or rejection.” The Court of Appeal held that it does, as the technical purpose – the communication of the negotiation result – is achieved. The decisive point is the understanding of the skilled person in light of the description; statements made by the applicant during prosecution may serve as supporting evidence but cannot independently limit the scope of protection.

Accordingly, the Court clarified that the objective technical meaning derived from the description remains decisive, and that the prosecution history does not constitute a primary source of interpretation. This approach – largely in line with expectations – enhances legal certainty for future interpretation disputes before the UPC.

5. “Offering” as an Act of Infringement under Article 25(a) UPCA

The Court of Appeal interpreted the concept of “offering” in an economic and autonomous manner. A legally binding offer is not required; even a mere presentation or invitation to submit an offer can constitute an act of infringement if it enables potential customers to acquire the patented product. Consequently, online product listings, catalogues, or advertisements may amount to infringement, even where no sale has yet occurred.

This broad interpretation – largely consistent with German law – reflects the realities of modern marketing practices. Companies operating within the UPC territory must therefore continue to review their advertising and sales activities carefully to avoid infringement risks.

6. Liability of Managing Directors

A central aspect of the Belkin judgment was the personal liability of managing directors. The Court clarified that mere corporate office does not give rise to liability. Personal liability exists only where the director deliberately uses the company as an instrument of infringement or, being aware of the infringement and its unlawfulness, fails to take reasonable steps to prevent it. This is likely to result, overall, in a management liability regime that is somewhat less strict than under German law, yet still one to be taken seriously.

The Court further emphasised that obtaining well-founded legal advice – for example, a non-infringement or freedom-to-operate opinion – may shield against liability, at least until a first-instance court has confirmed the infringement. As Philips had failed to show intentional or knowing participation by the Belkin directors, the Court lifted the injunctions issued against them.

7. Relationship with National Decisions

Belkin relied on an earlier German decision in which a Philips infringement claim had been dismissed. The Court of Appeal, unsurprisingly, rejected this argument: the res judicata effect of national judgments extends only to their operative part within the respective national territory and between the same parties. The reasoning and interpretation of a national court are not binding on the UPC, which under Articles 34 and 65 UPCA exercises independent jurisdiction.

8. Conclusion

The first substantive decisions of the UPC Court of Appeal – Seoul Viosys and Philips v. Belkin – may hold few surprises in substance, but they nonetheless represent an important milestone in the development of European patent litigation. They provide initial legal certainty on issues of disclosure, interpretation, infringement, and directors’ liability. Further decisions of the Court of Appeal in the coming months are eagerly awaited and will continue to shape the UPC’s emerging jurisprudence.

https://www.boehmert.de/wp-content/uploads/2025/10/Beitragsbild-UPC-Update-2.jpg 598 650 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2025-10-20 13:44:142025-10-21 10:29:42First Substantive Decisions of the UPC Court of Appeal: Seoul Viosys and Philips v. Belkin

BOEHMERT & BOEHMERT Seminar Downloads 2025 – Heidelberg Life Sciences

16. October 2025/in Uncategorized
Read more
/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Lucia Biehl /wp-content/uploads/2022/04/boehmert_logo.svg Lucia Biehl2025-10-16 11:03:052025-10-21 09:40:14BOEHMERT & BOEHMERT Seminar Downloads 2025 – Heidelberg Life Sciences

The UPC and its hardline stance on late filing

13. October 2025/in UPC-Update

All reasonably available evidence and arguments should be submitted as early as possible. Submitting prior art and arguments based on it at a later stage risks their rejection. Early investment is essential; the respective initial pleadings in the proceedings should be as airtight as possible.

In a decision of 7 March 2025 (UPC_CFI_459/2023), the LD Duesseldorf held in its headnotes that

“Strategic maneuvering aimed at achieving surprise effects is foreign to the rules of procedure”

and thus rejected new invalidity attacks that had only been raised in the respective oral hearing.
While such maneuvering was not uncommon in, for example, national German patent litigation, the UPC has already gone beyond such tame limitations, and has shaped the RoP via interpretation in a way that can only be described as “front loaded” in litigation speak, a term that is also expressively used in the case law of the CoA itself, see e.g. headnotes of CoA, order of 18 September 2024, UPC_CoA_264/2024 et al.
Meaning, that parties should not only abstain from raising entirely new arguments in the oral hearing, but arguments should instead be raised as early as possible. Such an approach ensures that the lines of argumentation in the course of a proceeding take the shape of a pyramid – becoming ever more focused on the contentious issues – rather than that of a branched tree, which was not too seldom the case in for example national German litigation.

General guidelines

While this approach is generally very reasonable in light of the aim of procedural efficiency, its application in practice can create headaches for parties and their representatives about what to search for and what to include in their first submissions. Since the details are far from being resolved, the general takeaway is

• Evidence for infringement, that was or could have been made available at the time of filing the statement of claim, risks being rejected if introduced later
• As far as infringement of a dependent claim could be argued, this should be done in the statement of claim
• In case there is already pre-trial exchange of the parties on infringement, evidence, validity, claim construction, prior art etc., this exchange should be fully included and also addressed in the statement of claim
• This also means, that in the absence of such pre-trial exchange, not every conceivable line of claim construction must be presented in the statement of claim, but a short description of the parts of the patent specification and the drawings which support the claimant’s claim construction
• Likewise, not every conceivable evidence must be presented, but every alleged fact should be supported by at least one piece of evidence, and may it just be a written testimony by the party
• The statement of defense must address all arguments, and all reasonably conceivable counterarguments should be included, with the weaker ones at least in a skeleton form
• This also applies to the counterclaim for revocation: all reasonably conceivable combinations of prior art for attacking inventive step should be included, with the weaker ones at least in skeleton form. Dependent claims should also be attacked, as far as possible
• All prior art than can be found, must be found!

The latter point cannot be stressed enough. In a recent order, the CoA confirmed a first instance decision that had rejected an application to amend a counterclaim for revocation, which was filed two days after the counterclaim. The counterclaimant had become aware of additional prior art, that a service provider tasked with researching prior art had seemingly overlooked, as this prior art popped up in an unrelated search of the counterclaimants patent attorney, which however used the same search string as the service provider (2 September 2025, UPC_CoA_807/2025).

Conclusion

This means that when properly researching prior art, not only should a reliable and able external service provider be commissioned, but its results should be double- and crosschecked by attorneys, if the budget allows. This further means that arguments that an external service provider did insufficient work and thus not being initially aware of certain prior art is not the fault of the respective party will likely not be heard, and that therefore not only the general quality of the provider should be considered, but also whether useful prior art might be found in specific domains (i.e. East Asian countries, academic publications) where different service providers might have the edge.

Lastly, this front-loaded approach means for claimants, that when the UPC or a national forum would both be available, specifically the German courts, and at least initial investment in the proceedings shall be on the lower side, the German courts might be more suitable, in order not to risk that a case is lost not because it had no merit, but because the investment could not match the front loading requirements of the UPC.

 

https://www.boehmert.de/wp-content/uploads/2025/10/UPC-Update-hardline-stance-on-late-filing.jpg 597 650 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2025-10-13 16:26:322025-10-14 08:40:41The UPC and its hardline stance on late filing
Dr. Rudolf Böckenholt, Attorney at Law at BOEHMERT & BOEHMERT

In GRUR Prax 19/2025, Dr. Böckenholt discusses two recent decisions on the concept of competitors in competition law

10. October 2025/in Publications

Definition of the concept of competitors. Contexts that lead to diverging interpretations of the concept of competitors. Detailed practical advice.

In his article „Mitbewerber durch funktionale Substitution: echte Divergenzen zwischen EuGH und BGH oder Einzelfälle“ (‘Competitors through functional substitution: genuine divergences between the Court of Justice of the European Union (CJEU) and the Federal Court of Justice (BGH) or individual cases’) in GRUR Prax, issue 19/2025, BOEHMERT & BOEHMERT partner and attorney at law Dr. Rudolf Böckenholt asks when a (sufficiently close) competitive relationship exists between two companies to be eligible for claims under the UWG (German Unfair Competition Act). In this context, the term ‘competitor’ must be defined under German and European law and it must be determined how broadly or narrowly this definition should be interpreted.

Against this background, Dr. Böckenholt compares a decision of the Court of Justice of the European Union (CJEU) of 8 May 2025 (GRUR 2025, 1001 – HUK-COBURG/Check24 = GRUR-Prax 2025, 367 [Baronikians]) with the ruling of the Federal Court of Justice (BGH) of 27 March 2025 (GRUR 2025, 589 – Fluggastrechteportal = GRUR-Prax 2025, 469 [Bärenfänger]). Both decisions deal with the status of competitors in digital contexts, but come to different conclusions: while the CJEU requires structural similarity of services, the Federal Court of Justice considers functional substitutability sufficient to establish a competitive relationship.

But what contexts lead to such divergent interpretations of the concept of competition? And what does this mean for legal advice? Dr. Böckenholt examines these questions in detail in his article and provides readers with comprehensive practical guidance.

The full article by Dr Rudolf Böckenholt is available for download in German to registered users of GRUR-Prax here.

 

https://www.boehmert.de/wp-content/uploads/2022/06/Boeckenholt-Rudolf-Potrait.jpg 667 1000 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2025-10-10 09:26:322025-10-13 09:54:17In GRUR Prax 19/2025, Dr. Böckenholt discusses two recent decisions on the concept of competitors in competition law

IP Summer Course 2026 in Munich

7. October 2025/in Uncategorized
Read more
/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Lucia Biehl /wp-content/uploads/2022/04/boehmert_logo.svg Lucia Biehl2025-10-07 10:51:212025-10-24 21:35:10IP Summer Course 2026 in Munich

Latest posts

  • Changes to the infringing product in ongoing UPC-proceedings11. November 2025 - 10:30
  • Excerpt from the flyer with an invitation to the Start-Up Workshops Frankfurt RheinMain, where BOEHMERT & BOEHMERT partner and patent attorney Dr. Daniel Herrmann will be speaking on November 20, 2025.
    Dr. Daniel Herrmann will speak on November 20, 2025, at the Start-Up Workshops Frankfurt RheinMain.10. November 2025 - 12:34
  • BOEHMERT & BOEHMERT recommended again in four legal areas in the JUVE Handbook of Commercial Law Firms 2025/267. November 2025 - 14:00

Categories

Archive

Menu

  • Firm
  • Our Practice
  • Career
  • News & Events
  • FIND EXPERTS
  • LinkedIn

Informations

  • Press
  • Contact
  • Legal notice
  • Data Protection
  • General Terms and Conditions
  • Contact

Legal Areas

  • Employee Inventions
  • Data Protection
  • Designs
  • Domains
  • Information Technology
  • Anti-Trust
  • Licensing
  • Trade Marks
  • Patent Valuation
  • Patents & Utility Models
  • Patent Litigation
  • Product Piracy
  • Copyright
  • Unfair Competition

© Copyright 2025– BOEHMERT & BOEHMERT

Scroll to top Scroll to top Scroll to top
Cookie settings Cookie settings

We need your consent before you can continue to use our website.


If you are under 16 and wish to give your consent to volunteer services, you must ask your parent or guardian for permission. We use cookies and other technologies on our website. Some of them are essential, while others provide you with more advanced information. For more information about how we use your data, please see our Data Protection Policy. There is no obligation to consent to the processing of your data in order to use this offer. You can revoke or adjust your selection at any time under Settings. Please note that due to individual settings, not all functions of the website may be available.

Cookie settings

Accept all cookies

Save settings

Accept only essential cookies

Individual data protection settings

Cookie details Privacy policy Legal notice

Cookie settings Cookie settings

If you are under 16 and wish to give your consent to volunteer services, you must ask your parent or guardian for permission. We use cookies and other technologies on our website. Some of them are essential, while others provide you with more advanced information. For more information about how we use your data, please see our Data Protection Policy. There is no obligation to consent to the processing of your data in order to use this offer. Please note that due to individual settings, not all functions of the website may be available. Here you can find an overview of all cookies used. You can give your consent to entire categories or view more information and thus select only certain cookies.

Accept all cookies Save settings Accept essential cookies only

Back

Cookie settings

Essential cookies enable basic functions and are necessary for the proper functioning of the website.

Display cookie information Hide cookie information

Name
Provider Borlabs GmbH, Legal notice
Purpose Stores the settings of the visitors selected in the Cookie Box of Borlabs Cookie.
Data protection policy https://borlabs.io/privacy/
Cookie name borlabs-cookie
Cookie duration 1 year

Content from video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Display cookie information Hide cookie information

Accept
Name
Provider Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Purpose Used to unlock YouTube content.
Data protection policy https://policies.google.com/privacy
Host(s) google.com
Cookie name NID
Cookie duration 6 months

Privacy policy Legal notice